23 Results for "

SRF

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "SRF" in MCE Product Catalog:

15
15 Publications Verification
Cat. No.: HY-13991
CAS No.: 285986-88-1
Purity:  99.88%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108361
CAS No.: 1443437-74-8
Purity:  99.89%
Target:  

Ras

Research Areas:  

Inflammation/Immunology Cancer

CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-120855
CAS No.: 1207113-88-9
Purity:  99.29%
Target:  

Ras

Research Areas:  

Cardiovascular Disease

CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99533
CAS No.: 2249722-58-3
Synonyms: SRF-231; SRF231

Research Areas:  

Cancer

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
loading...
    loading...
Cat. No.: HY-111432
CAS No.: 1922099-21-5
Purity:  99.00%
Target:  

Ras

Research Areas:  

Others

CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
loading...
    loading...
Cat. No.: HY-P991061
CAS No.: 3024486-14-1
Synonyms: CHS-114; SRF-114

Target:  

CCR

Research Areas:  

Cancer

Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8 + T cell subsets. Tagmokitug can be used for the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P990024
CAS No.: 2643331-37-5
Synonyms: SRF-388

Target:  

Interleukin Related

Research Areas:  

Cancer

Casdozokitug (SRF-388) is an IgG1κ antibody targeting IL27 .
loading...
    loading...
Cat. No.: HY-P990068
CAS No.: 2643331-31-9
Synonyms: SRF617

Target:  

NTPDase

Research Areas:  

Inflammation/Immunology Cancer

Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 + T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .
loading...
    loading...
Cat. No.: HY-153078
CAS No.: 1922098-90-5
Purity:  99.68%
Target:  

Ras

Research Areas:  

Cancer

MRTF/SRF-IN-1 (example 41) is an inhibitor of both myocardin-related transcription factor and serum response factor (MRTF/SRF). MRTF/SRF-IN-1 can be used for research for preventing cancer and fibrosis .
loading...
    loading...
Cat. No.: HY-132187
CAS No.: 1670-26-4
Purity:  99.50%
Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a Kd of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes .
loading...
    loading...
Cat. No.: HY-162904
CAS No.: 2198977-68-1
Research Areas:  

Cardiovascular Disease

BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .
loading...
    loading...
Cat. No.: HY-RS13760
Research Areas:  

Others

SRF Human Pre-designed siRNA Set A contains three designed siRNAs for SRF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-118748
CAS No.: 1477482-50-0
Purity:  ≥98.0%
Synonyms: SRF
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .
loading...
    loading...
Cat. No.: HY-130011
CAS No.: 2349373-70-0
Target:  

ROCK Ras

Research Areas:  

Neurological Disease Cancer

CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression .
loading...
    loading...
Cat. No.: HY-13991R
CAS No.: 285986-88-1
Target:  

Ras Apoptosis

Research Areas:  

Cancer

CCG-1423 (Standard) is the analytical standard of CCG-1423. This product is intended for research and analytical applications. CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
loading...
    loading...
Cat. No.: HY-162968
Target:  

Ras

MRTF-A-in-1 (Compound 14) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging .
loading...
    loading...
Cat. No.: HY-162969
Target:  

Ras

MRTF-A-in-2 (Compound 16) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging .
loading...
    loading...
Cat. No.: HY-RS17529
Research Areas:  

Others

Srf Mouse Pre-designed siRNA Set A contains three designed siRNAs for Srf gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS23985
Research Areas:  

Others

Srf Rat Pre-designed siRNA Set A contains three designed siRNAs for Srf gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-108361R
CAS No.: 1443437-74-8
Target:  

Reference Standards Ras

Research Areas:  

Inflammation/Immunology Cancer

CCG-203971 (Standard) is the analytical standard of CCG-203971 (HY-108361). This product is intended for research and analytical applications. CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
loading...
    loading...